Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.22 USD
-0.12 (-5.13%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $2.23 +0.01 (0.45%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
05/09/2024
Time: -- |
3/2024 | $-0.15 | 0.00% |
Earnings Summary
For their last quarter, Regulus Therapeutics (RGLS) reported earnings of -$0.40 per share, in line with the Zacks Consensus Estimate. This reflects a breakeven earnings surprise. Look out for RGLS's next earnings release expected on May 09, 2024. For the next earning release, we expect the company to report earnings of -$0.15 per share, reflecting a year-over-year increase of 64.29%.
Earnings History
Price & Consensus
Zacks News for RGLS
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS: What are Zacks experts saying now?
Zacks Private Portfolio Services